Golden Guard Financial News | TaiMei Medical Technology (02576) will publicly offer shares from today until October 3, intending to globally sell 22.4166 million H shares, with 10% for public sale in Hong Kong, the rest for international allocation, and an additional 15% over-allotment option. The offering price per share ranges between 10-13 Hong Kong dollars, with 200 shares per board lot and an entry fee of 2,626.22 Hong Kong dollars. The shares will be officially listed on October 8 (Tuesday). Morgan Stanley and China International Capital Corporation are the joint sponsors.

Based on the midpoint price of 11.5 Hong Kong dollars, the net proceeds will be 0.1857 billion Hong Kong dollars. Around 35% of the proceeds will be used to optimize and upgrade the TrialOS platform, PharmaOS platform, and their respective cloud software and digital services; about 30% will be allocated to enhance the group's core technology and research and development capabilities; around 10% will be utilized to strengthen our sales and marketing capabilities; approximately 15% will be earmarked for selectively seeking strategic investments and acquisitions that the group believes will expand the existing product and service categories, grow the customer base, and enhance technological capabilities; and roughly 10% will be allocated for working capital and general corporate purposes.